 
  Study ID: [REMOVED] 
  Protocol Number: SJP-0132/1-01 
  
Study Title:  
A Randomized, Double -Masked, Single -Center, Placebo -Controlled Single and 
Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, 
and Efficacy of SJP -0132 in Subjects with Dry Eye Disease  
 
 Protocol Version:  Version 3.0: 12 December, 2019  
 
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 7 of 75 
Status: Final v3.0; Date 1 2Dec2019 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY 
Document  Date 
Amendment 1 (Protocol Version 3.0) 12 Dec 2019  
Revision (Protocol Version 2.0)  21 Aug 2019  
Original Protocol  (Protocol Version 1.0) 29 July 2019 
 
Amendment  1 (12 Dec 2019) 
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
because it neither significantly impacts the safety or physical integrity of participants nor the scientific value of the study.  
Overall Rationale for th e Amendment:  
The timing of some of the End-of- Study assessments for Part B was modified.  
Section # and 
Name Description of Change  Brief Rationale 
2, Schedule of 
Activities, Part B, 
EOS Shifted hematology, serum chemistry, 
urinalysis, and serum pregnancy test to 2h 
postdose. 
Shifted physical examination, weight, and 
vital signs to 4h postdose. 
Shifted visual acuity (Snellen), slit lamp 
biomicroscopy w/out mydriatics, Schirmer I w/o anesthesia, intraocular pressure, slit 
lamp biomicroscopy w/ mydriatics (le ns 
observation), and ophthalmoscopy to 8h 
postdose. 
 Adjustments to timing of 
assessments to occur after 
dosing. 
9, Study 
Assessments and 
Procedures, Part 
B, Day 29 ±2, EOS Timing of assessments modified according to Schedule of Activities  Consistency 
Revision 1 (21 Aug  2019) 
Minor editorial changes only. This version was submitted to the US Food and Drug Administration.
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 8 of 75 
Status: Final v3.0; Date 1 2Dec2019 Table of Contents  
 
STUDY ADMINISTRATION .....................................................................5  
Protocol Amendment Summary of Changes Table .....................................7  
Table of Contents .........................................................................................8  
1. Synopsis......................................................................................11  
2. Schedule of Activities (SoA)  .....................................................16  
3. Introduction ...............................................................................20  
3.1. Study Rationa le ...........................................................................22  
3.2. Background .................................................................................22  
3.2.1.  Nonclinical Studies  .....................................................................22  
3.2.2.  Clinical Studies  ...........................................................................25  
3.2.3.  Efficacy .......................................................................................26  
3.2.4.  Safety ..........................................................................................26  
3.3. Benefit/Risk Assessment  ............................................................26  
4. Objectives and Endpoints  ........................................................28  
5. Study Design  ..............................................................................29  
5.1. Overall Design  ............................................................................29  
5.2. Subject and Study Completion ...................................................30  
5.3. End of Study Definition ..............................................................30  
5.4. Scientific Rationale for Study Design  ........................................31  
5.5. Justification for Dose ..................................................................31  
6. Study Population  .......................................................................32  
6.1. Inclusion Criteria  ........................................................................32  
6.2. Exclusion Criteria  .......................................................................32  
6.3. Lifestyle Restrictions  ..................................................................34  
6.3.1.  Meals and Dietary Restrictions  ...................................................34  
6.3.2.  Caffeine, Alcohol, and Tobacco .................................................34  
6.3.3.  Activity .......................................................................................34  
6.4. Screen Failures  ............................................................................34  
7. Treatments  .................................................................................35  
7.1. Treatments Administered  ............................................................35  
7.2. Investigational Product Information ...........................................35  
7.3. Preparation/Handling/Storage/Accountability  ............................35  
7.4. Dose Modification ......................................................................35  
7.5. Method of Treatment Assignment ..............................................36  
7.6. Masking ......................................................................................36  
7.7. Missed Doses ..............................................................................37  
7.8. Concomitant Therapy .................................................................37  
7.8.1.  Recording Prior and Concomitant Medications ..........................37  
7.8.2.  Prohibited Concomitant Medications, Treatments, and Procedures  ...................................................................................37
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 9 of 75 
Status: Final v3.0; Date 1 2Dec2019 7.8.3.  Rescue Medicine  .........................................................................37  
7.9. Treatment after the End of the Study ..........................................37  
8. Discontinuation/Withdrawal Criteria  .....................................38  
8.1. Discontinuation of Study Treatment ...........................................38  
8.2. Withdrawal from the Study .........................................................38  
8.3. Lost to Follow Up .......................................................................39  
9. Study Assessments and Procedures .........................................40  
9.1. Efficacy Assessments  .................................................................50  
9.2. Safety Assessments  .....................................................................51  
9.2.1.  Ocular Safety  ..............................................................................51  
9.2.2.  Physical Examinations  ................................................................52  
9.2.3.  Vital Signs  ...................................................................................52  
9.2.4.  Clinical Safety Laboratory Assessments  ....................................53  
9.3. Adverse Events  ...........................................................................53  
9.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  .................................................................................53  
9.3.2.  Method of Detecting AEs and SAEs ..........................................54  
9.3.3.  Follow-up of AEs and SAEs .......................................................54  
9.3.4.  Regulatory Reporting Requirements for SAEs ...........................54  
9.3.5.  Pregnancy  ....................................................................................54  
9.4. Treatment of Overdose  ...............................................................55  
9.5. Pharmacokinetics  ........................................................................55  
9.6. Health Economics  .......................................................................56  
10. Statistical Considerations .........................................................56  
10.1.  General Considerations ...............................................................56  
10.2.  Sample Size Determination  ........................................................56  
10.3.  Populations for Analyses ............................................................57  
10.4.  Statistical Analyses  .....................................................................57  
10.4.1.  Efficacy Analyses  .......................................................................58  
10.4.2.  Safety Analyses  ...........................................................................59  
10.4.3.  Pharmacokinetic Analyses  ..........................................................59  
11. References  ..................................................................................60  
12. Appendices  .................................................................................61  
Appendix 1: Abbreviations and Terms ......................................................61  
Appendix 2: Clinical Laboratory Tests  ......................................................63  
Appendix 3: Study Governance Considerations ........................................64  
Appendix 4: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ........................................67  
Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information  .................................................................................73  
  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 10 of 75 
Status: Final v3.0; Date 1 2Dec2019 In-Text Tables 
Table 9-1: Volume of Blood to be Collected from Each Subject  .........40 
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 15 of 75 
Status: Final v3.0; Date 1 2Dec2019 Statistical Methods  
The primary statistical analysis of the data will be descriptive in nature. For continuous variables 
this means calculation of the number of observations, mean, standard deviation, median, 
minimum, and maximum. Categorical variables will be summarized by subject counts and 
related percentages. For ordinal -scaled variables, a combination of the above may be employed 
as appropriate:  frequency  and percentage of observations within a category and means and 
standard deviations of the scores of the categories. For categorical and ordinal variables, 
percentages will be calculated based on non -missing data.  
Sample Size Determination:  
No formal sample size and/or power calculations were performed for the study, however a sample 
size was chosen based on feasibility to allow total of 92 randomized subjects for Part A (n=32) 
and Part B (n= 60). Approximately 32  subjects are expected to comp lete Part A and 60 subjects are 
expected to complete Part B.  
Safety Analysis: 
Safety assessments and changes from baseline in vital signs, clinical laboratory results, adverse 
events (AEs), will be summarized using descriptive statistics (mean, standard deviation, 
coefficient of variation (%CV), median, minimum, and maximum). Concomitant medications and 
physical examination findings will be listed.  
Efficacy Analysis: 
The study eye will be th e eye with the greater central zone corneal fluorescein staining. If both 
eyes meet all of the inclusion and none of the exclusion criteria and the central zone corneal 
fluorescein staining scores are equal, the right eye (OD) will be designated as the stu dy eye for the 
duration of this study.  
The fellow eye (non- study eye) will be treated with the product as per the assigned dosing 
schedule. 
Change in eye assessments  will be summarized using descriptive statistics (mean, standard 
deviation, coefficient of  variation (%CV), median, minimum, and maximum). The primary 
endpoint is the difference between SJP -0132 and placebo in changes in eye dryness symptom 
(visual analog scale [VAS]) . Secondary endpoints are changes in dry eye signs (vital staining of 
cornea, conjunctiva and lid margin, tear film break -up time (TFBUT) , and changes in dry eye 
symptoms (VAS  [ie, severity of eye dryness, discomfort , burning/stinging, sticky feeling, foreign 
body sensation, itching, pain, blurred vision, and sensitivity to light], ocular surface disease index 
[OSDI], Dry eye Questionnaire 5 [DEQ-5] scores). 
Pharmacokinetic Analysis: 
Plasma samples will be analyzed to determine the concentration of SJ P-0132. Pharmacokinetic 
variables will be calculated using non- compartmental analysis. Part A: Cmax, tmax, tlast, AUC0-last, 
AUC0-∞, AUC %extrap, t1/2, AUMC 0-last, AUMC 0-∞, MRT0-last, MRT0-∞, Vd/F, CL/F, Cmax,norm, 
AUC0-last,norm, AUC0-∞,norm. Part B: Cmax, tmax, tlast, AUC 0-last, Cmax,norm, and AUC0-last,norm on Day 1, 
Ctrough on Days 2, 4 and 8, and Rac. The PK data will be summarized using descriptive statistics 
and will also be displayed graphically as appropriate. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 16 of 75 
Status: Final v3.0; Date 1 2Dec2019 2. Schedule of Activities  (SoA) 
Part A (SAD)  Screen Run-in Check 
In Treatment Phase  Check 
Out 
Procedure  
All 0h assessments will be performed prior 
to Drug administration . Day -30  
to  
Day -15 Day -14 
(+2)5 
to  
Day -2 Day -1 Day 1 Day 2 
0 h 0.25 h 0.5 h 1 h 2 h 4 h 8 h 12 h 0 h 
Informed Consent / HIPAA  X                       
Demography  X            
Medical / Surgical History X    X                    
Inclusion/Exclusion Criteria  X    X                    
Physical Examination1 X     X     X         X 
Height X            
Weight X  X          
Vital signs2 X    X X   X X X X X X X 
DEQ-5 3 X   X                    
VAS 3 X   X X   X X X X X X X 
OSDI© 3 X   X                   
Hematology, Serum Chemistry, Urinalysis  X    X                  X 
Serology (HIV, HBsAg, HCV)  X                        
Serum pregnancy test and FSH ( WOCBP only) X                        
Pharmacokinetic Sampling         X X X X X X X X  
Urine drug and alcohol screen  X    X                    
Urine Pregnancy Test       X                    
Visual Acuity (Snellen)  X   X               X X 
Slit lamp biomicroscopy (w/out mydriatics)  X     X     X X     X X 
Matrix Metalloproteinase -9 (MMP-9)4 X   X                   
TFBUT X     X      X     X X 
Corneal fluorescein staining (Baylor)  X   X X      X     X X 
Lissamine green  staining (Baylor + Lid Margin)  X     X                 
Aesthesiometer  X             
Schirmer I w/o anesthesia  X   X                X X 
VAS w/ anesthesia  X                       
Intraocular Pressure (iCare tonometer)  X     X       X     X X 
Slit lamp biomicroscopy (w/ mydriatics; lens 
observation)  X   X               X X 
Ophthalmoscopy  X   X               X X 
Record and assess adverse events   Continuous  
Concomitant Medications   Continuous  
Confinement Period    X 
Randomization        X                 
Drug Administration    Placebo6 Placebo6 X                 
HIPAA = Health Information Portability and Accountability Act; VAS = Visual Analog Scale;  TFBUT = Tear film break -up time; OSDI = Ocular 
Surface Disease Index ; WOCBP = women of child -bearing potential  
1 Physical Examination includes head -eye-ears-nose-throat, cardiovascular, respiratory, gastrointestinal, dermatologic, and neurologic examinations.  
2 Blood pressure, heart rate, respiratory rate, oral temperature.             
3 Questionnaires will be completed prior to lab or PK timepoints. Ophthalmic assessments will follow lab or PK timepoints.  
4 30 minutes before staining tests               
5 Day -14 can be completed within +2 days (Day -14 to Day -16), however Placebo Run -In dosing will begin on Day -14 per protocol  
6 For Placebo Run -In (Day -14 visit) subjects will be dispensed placebo and educated in administration and dosing diary completion.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 17 of 75 
Status: Final v3.0; Date 1 2Dec2019 Part B (MAD) (3 pages) Screen Run-In Check In Treatment Period  
Procedure  
All 0h assessments will be performed prior to  
Drug administration . Day -30 
to 
Day -15 Day -14 
(+2)5  
to 
Day -2 Day –1 Day 1 Day 2 Day 3 
0 h 0.25 h 0.5 h 1 h 2 h 4 h 8 h 12 h 0 h 4 h 8 h 12 h 0 h 4 h 8 h 12 h 
Informed Consent/HIPAA   X                                    
Demography  X                   
Medical/Surgical history X   X                                
Inclusion/Exclusion Criteria  X   X                                
Physical examinations1 X      X     X         X       X       
Height X                   
Weight X  X                 
Vital signs2 X   X X   X X X X X X X X X X X X X X 
DEQ-5 3 X   X                                
VAS 3  X   X X    X X X X X X X X X X X X X X 
OSDI© 3 X   X                               
Hematology, Serum Chemistry, Urinalysis  X   X                                
Serology (HIV, HBsAg, HCV)  X                                    
Serum pregnancy test and FSH ( WOCBP only) X                                    
Pharmacokinetic Sampling        X  X X X X X     X               
Urine drug and alcohol screen   X   X                                
Urine pregnancy test      X                                
Visual acuity  (Snellen) X   X               X X       X      
Slit lamp biomicroscopy  (w/out mydriatics)   X      X     X X    X X     X X     X 
Matrix Metalloproteinase -9 (MMP-9)4 X   X                                
TFBUT   X     X        X    X X     X X     X 
Corneal fluorescein staining (Baylor)   X   X X        X    X X     X X     X 
Lissamine  green staining (Baylor +Lid Margin)  X      X            X X     X X     X 
Aesthesiometer   X                    
Schirmer I w/o anesthesia  X   X               X X               
 VAS w/ anesthesia  X                                      
Intraocular pressure  (iCare tonometer)  X     X              X X       X       
Slit lamp biomicroscopy (w/ mydriatics; lens 
observation)  X   X               X                
Ophthalmoscopy  X   X               X                
Record and assess adverse events     Continuous  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 18 of 75 
Status: Final v3.0; Date 1 2Dec2019 Part B (MAD) (3 pages) Screen Run-In Check In Treatment Period  
Procedure  
All 0h assessments will be performed prior to  
Drug administration . Day -30 
to 
Day -15 Day -14 
(+2)5  
to 
Day -2 Day –1 Day 1 Day 2 Day 3 
0 h 0.25 h 0.5 h 1 h 2 h 4 h 8 h 12 h 0 h 4 h 8 h 12 h 0 h 4 h 8 h 12 h 
Concomitant medications     Continuous  
Confinement Period      Day -1 until Day 8  
Randomization        X                               
Drug administration    Placebo6  Placebo6  X         X X X X X X X X X X X 
HIPAA = Health Information Portability and Accountability Act; VAS = Visual Analog Scale; TFBUT = Tear film break -up time; OSDI = Ocular Surface Disease Index; WOCBP = women of 
childbeari ng potential; FSH = follicle stimulating hormone  
1 Physical Examination includes head -eye-ears-nose-throat, cardiovascular, respiratory, gastrointestinal, dermatologic, and neurologic examinations.  
2 Blood pressure, heart rate, respiratory rate, oral temperature.  
3 Questionnaires will be completed prior to lab or PK timepoints. Ophthalmic assessments will follow lab or PK timepoints.  
4 30 minutes before staining tests  
5Day -14 can be completed within +2 days (Day -14 to Day -16), however Placebo Run -In will begin on Day -14, per protocol  
6 For Placebo Run -In (Day -14 visit) subjects will be dispensed placebo and will be educated in self -administration and dosing diary c ompletion.  
  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 19 of 75 
Status: Final v3.0; Date 1 2Dec2019 Part B (MAD) (3 Pages ) Treatment Period (continued)  EOS Follow 
Up 
Procedure  
All 0h assessments will be performed prior 
to Drug administration . Day 4 to Day 7 Day 8 
(Check Out)  Day 9 to  
Day 28 dosing  Outpatient Visit  
Days 15±2, 22±2 Day 29±2  Day 
36±2 
0 h 0.5 h 1h 2h 4h 8h 12h 0 h  4 h 8 h 12 h 0 h  4 h 8 h 12 h 0 h 4 h 8 h 12 h 0 h  2 h 4 h 8 h   
Physical examinations1 X             X               X          X    
Weight                      X   
Vital signs2 X             X               X      X    
DEQ-5 3                                      X       
VAS3,4 X X X X X  X  X X               X X X  X  X X   
OSDI© 3               X               X       X      
Hematology, Serum Chemistry, Urinalysis                X                        X      
Serum pregnancy test  (for WOCBP only)                                         X      
Pharmacokinetic Sampling  X5             X                                
Visual Acuity (Snellen)  X            X               X          X   
Slit lamp biomicroscopy  w/out mydriatics   X           X X               X          X   
Matrix Metalloproteinase -9 (MMP-9)6                                      X         
TFBUT   X         X X               X       X         
Corneal fluorescein staining (Baylor)   X         X X               X       X         
Lissamine  green staining (Baylor +Lid 
Margin)  X         X X               X       X         
Schirmer I  w/o anesthesia                X                           X   
Intraocular pressure  (iCare tonometer)                X               X            X   
Slit lamp biomicroscopy  w/ mydriatics  
(lens observation)                  X                           X   
Ophthalmoscopy                 X                           X   
Record and assess adverse events   Continuous    
Concomitant medications  Continuous    
Confinement Period  X Out7                 
Drug administration  X       X X X X X X X X X X X X X X X X     
Telephone call                                              X 
 EOS = End  of Study Assessments; VAS = Visual Analog Scale; TFBUT = Tear film break -up time; OSDI = Ocular Surface Disease Index ; WOCBP = women of childbearing potential  
 1 Physical Examination includes head -eye-ears-nose-throat, cardiovascular, respiratory, gastrointestinal, dermatologic, and neurologic examinations.  
2 Blood pressure, heart rate, respiratory rate, oral temperature.  
3 Questionnaires will be completed prior to lab or PK timepoints. Ophthalmic assessments will follow lab or PK timepoints.  
4VAS assessment completed on Day 4 & 7 at 0h, 0.5h, 1h, 2h, 4h, 8h,  12h timepoints. VAS on Days 5 & 6 at 0, 4, 8, and 12 h  
5 Day 4 only  
6 30 minutes before staining tests  
7 Check-out after completion of all Day 8 assessments and 0 h dosing  
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 28 of 75 
Status: Final v3.0; Date 1 2Dec2019 4. Objectives and Endpoints  
Objectives  Endpoints 
Primary 
• Safety and tolerability 
of SJP-0132 • The number and severity of AEs including abnormal 
changes in clinical laboratory results, vital signs, and 
physical and ophthalmologic examinations  
• Pharmacokinetic (PK) 
profiles of SJP -0132  • Part A: Cmax, tmax, tlast, AUC0-last, AUC 0-∞, t1/2, AUC%extrap, 
AUMC0-last, AUMC 0-∞, MRT0-last, MRT0-∞, Vd/F, CL/F, 
Cmax,norm, AUC 0-last,norm, and AUC 0-∞,norm 
• Part B: Cmax, tmax, tlast, AUC 0-last, Cmax,norm, and AUC0-
last,norm on Day 1, C trough on Days 2, 4 and 8, and Rac  
• Efficacy of SJP -0132 • Change from baseline (predose on Day 1) in eye dryness  
symptom (visual analog scale [VAS])  at 4 hours on Day 29  
• Change from baseline (predose on Day 1) in corneal 
fluorescein staining (CFS) score at the central zone on Day 
29 
Secondary  
• Efficacy of SJP -0132 
 
 • Changes from baseline  in dry eye signs : CFS scores at the 
central, superior, inferior, nasal, temporal and total zones, 
conjunctival lissamine green staining (CLGS) scores at 
each of 3 nasal and 3 temporal zone and total zone of 
bulbar conjunctiva , lid wiper epitheliopathy score , and tear 
film break -up time (TFBUT)  at each time point tested  
• Changes from baseline  in dry eye symptoms (VAS  [ie, 
severity of eye dryness, discomfort , burning/stinging, 
sticky feeling, foreign body sensation, itching, pain, 
blurred vision, and sensitivity to light] , ocular surface 
disease index [OSDI], Dry eye Questionnaire 5 [DEQ -5] 
scores) at each time point tested  
• Biomarker (Matrix Metalloproteinase -9 (MMP -9), 
InflammaDry®) 
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 33 of 75 
Status: Final v3.0; Date 1 2Dec2019 5. Have used or anticipates use of any prescription or over-the- counter medication, including 
topical medications such as ophthalmic solutions (except an ophthalmic solution specially 
provided by Sponsor, mydriatics, and stain used for trial examinations) , nasal drops or 
spray, vitamins, alternative and complementary medicines (including herbal formulations) 
within 14 days or 5 half-lives (whichever is longer)  before randomization or at any time 
during the study.  
6. Use or anticipates use of prescribed dry eye medication s (e.g. Restasis and Xiidra)  within 
28 days prior to randomization or at any time during the study. 
7. Have used  or anticipates use CYP3A4 inducers, such as St. John’s Wort, within 14 days 
before randomization or at any time during the study . 
8. Have consumed red wine, grapefruit or grapefruit juice, Seville oranges, star fruit, or any 
products containing these items, or any foods that may inhibit CYP3A4, within 48 hours before randomization and throughout the duration of the study 
9. Have a positive urine alcohol t est at Screening or Day –1   
10. Have a positive urine drug test at Screening or Day –1   
11. Has history of, or evidence of, alcohol or drug abuse within past 6 months prior to 
Screening  
12. Have a positive HBsAg, HCV antibody, or HIV test at Screening  
13. Have received another investigational medication within 90 days before randomization  
14. Contact lens wearers who cannot discontinue the wear over the trial period (i.e., from 
Screening to EOS)  
15. Have undergone eye surgery (including laser surgery) within the last 12 mont hs or whom 
the Investigator considers unsuitable  
16. Subjects whom the Investigator considers are unable or unlikely to comply with the trial 
protocol or scheduled Screening or Admission (e.g., planned travel outside of the trial area for a substantial portion of the trial period, scheduled hospitalization during the trial period)  
17. Have a family history of sudden death  
18. Have cardiac disease (e.g., cardiac arrest, ischemic cardiac disease)  
19. Have abnormal serum electrolytes according to the judgment of the Investigator  
20. Have a BCVA worse than 20/100 in either eye. 
21. Current use of punctal plugs or anticipated insertion during study period. 
22. History of permanent punctal occlusion (cautery or laser).  
23. Any corneal abnormality or disease which might impact normal tear film spreading (eg: cornea scarring, keratoconus or pterygia).  
24. Active or history of significant corneal disease (recurrent erosions or herpetic keratitis). 
25. Known allergy or sensitivity to fluorescein, lissamine green or any of the study 
medications.  
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 34 of 75 
Status: Final v3.0; Date 1 2Dec2019 6.3. Lifestyle Restrictions  
6.3.1. Meals and Dietary Restrictions  
1. Refrain from consumption of red wine, grapefruit or grapefruit juice, Seville oranges, star 
fruit, or any products containing these items, or any foods that may inhibit CYP3A4, 
within 48 hours before randomization and throughout the duration of the study . 
6.3.2. Caffeine, Alcohol, and Tobacco 
1. Subjects will abstain from ingesting caffeine - or xanthine -containing products ( eg, coffee, 
tea, cola drinks, and chocolate) for 24 hours prior to  the start of dosing on Day 1 of Part A 
and Days 1, 2, 4, and 8 of Part B, and for the remainder of the confinement period until 
after collection of the final pharmacokinetic ( PK). Subjects will also abstain 24 hours prior 
to each weekly outpatient visit.  
2. Subjects will abstain from alcohol for 24 hours before the start of dosing on Day 1 of Part 
A and Days 1, 2, 4, and 8 of Part B until after collection of the final pharmacokinetic ( PK).  
3. Use of tobacco products will not be allowed from screening until after the final follow -up 
visit. 
6.3.3. Activity 
1. Subjects will abstain from strenuous exercise for 24 hours before each blood collection for 
clinical laboratory tests.  Subjects may participate in light recreational activities during 
studies (eg, watching television, reading).  
2. Subjects will be asked to refrain from the following for 24 hours prior to their visits:  
• Dangerous sport activities ( eg, skiing, mountain climbing, etc.) 
• Swimming in a chlorinated pool 
• Challenging climates ( eg, smoking rooms, sauna, etc.) 
6.4. Screen Failures  
Screen failures are defined as subjects who consent to participate in the clinical study but are not 
subsequently entered in the study . A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting 
Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious adverse event  (SAE). 
Individuals who do not meet the criteria for participation in this study (screen failure) may not  be 
rescreened. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 37 of 75 
Status: Final v3.0; Date 1 2Dec2019 after breaking the mask. The date and reason that the mask was broken must be recorded in the 
source documentation and CRF, as applicable. 
7.7. Missed Doses 
If a dose is missed, the subject should dose as soon as they remember and adjust subsequent 
doses for that calendar day at 4 -hour intervals, resuming protocol-indicated dosing on the next 
calendar day. Subject will record Date and time of actual dosing in the provided diary. 
7.8. Concomitant Therapy  
7.8.1. Recording Prior and Concomitant Medicatio ns 
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, and/or 
herbal supplements) that the subject is receiving at the time of enrollment or receives during the 
study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates 
• Dosage information including dose and frequency 
The Medical Monitor should be contacted if there are any questions regarding concomitant or prior 
therapy. 
7.8.2. Prohibited Concomitant Medications, Treatments, and Procedures  
Subjects must abstain from taking prescription or nonprescription drugs (including topical 
medications such as ophthalmic solutions  [except an ophthalmic solution specially provided by 
Sponsor, mydriatics, and stain used for trial examinations ], nasal drops or spray, vitamins, 
alternative and complementary medicines [including herbal formulations ] ) within 14 days or 5 
half-lives (whichever is longer) before randomization until completion of the follow -up visit, 
unless, in the opinion of the investigator and sponsor, the medication will not interfere with the 
study. Subjects must refrain from use of CYP3A4 inducers, such as St. John’s Wort, for 14 days 
before randomization or at any time during the study . Subjects must abstain from prescribed d ry 
eye medications ( e.g. Restasis and Xiidra ) for 28 days before randomization or at any time during 
the study. 
7.8.3. Rescue Medicine 
No rescue medication will be provided. 
7.9. Treatment a fter the End of the Study 
Study medication will not be provided after the end of the study. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 38 of 75 
Status: Final v3.0; Date 1 2Dec2019 8. Discontinuation/Withdrawal Criteria  
A subject may voluntarily discontinue participation in this study at any time.  It is important to 
document whether the withdrawal of consent is primarily due to an AE or other reason.  The 
Investigator ma y also, at his or her discretion, discontinue the subject from participating in this 
study at any time.  Withdrawn subjects will not be replaced.  
Subjects may be prematurely discontinued from the study for any of the following reasons: 
• Subject non- compliance 
• Investigator non-compliance 
• Subject requires concurrent prohibited medication during the course of the study.  If, in 
the opinion of the Investigator and the study medical monitor, such medication will not 
interfere with the conduct or interpretation of the study or compromise the safety of the subject, then the subject may continue to receive study medication.  If the subject is discontinued from study medication, they would remain in the study for safety assessments as needed.    
• Pregnancy of female subject  
• Discontinuation of the study at the request of the Sponsor, regulatory agency or an 
Institutional Review Board / Independent Ethics Committee  
• Grade 3 or 4 clinical AE considered causally related to treatment.  
If a subject meets a withdrawal criterion during treatment, procedures listed in the SoA
 for Part A 
check-out or Part B Day 29 EOS will be required . 
8.1. Discontinuation of  Study Treatment   
If a clinically significant finding is identified after enrollment, the investigator or qualified 
designee will determine if the subject can continue in the study  and if any change in subject 
management is needed . Any new clinically relevant finding should be reported as an AE.  
Procedures listed in the  SoA for Part A  check-out or Part B Day 29 EOS should be completed at 
the time of treatment discontinuation . 
8.2. Withdrawal from the Study  
• A subject may withdraw from the study at any time at his/her own request or  may be 
withdrawn at any time at the discretion of the investigator  for safety, behavioral , 
compliance, or administrative reasons. 
• If the subject withdraws consent  for disclos ure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent . 
• If a subject withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records . 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 39 of 75 
Status: Final v3.0; Date 1 2Dec2019 • At the time of study discontinuation the End-of-Study procedures need to be completed . 
8.3. Lost to Follow Up  
A subject will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject fails to return to the clinic for a required study 
visit: 
• The site must attempt to contact the subject and reschedule the m issed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in the 
study. 
• Before a subject is deemed lost to follow up, the investigator or designee must make every 
effort to regain contact with the subject (where possible, 3 telephone calls and , if necessary , 
a certified letter to the subject’s last known mailing address or local equivalent methods). 
These contact attempts should be documented in the subject’s medical record . 
• Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the study with a primar y reason of lost to f ollow-up.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 40 of 75 
Status: Final v3.0; Date 1 2Dec2019 9. Study Assessments and Procedures  
• Study procedures and their timing are summarized in the SoA .  
• Protocol waivers or exemptions are not allowed. 
• Immediate  safety concerns  should be discussed with the sponsor immediately upon occurrence 
or awareness to determine if the subject  should continue or discontinue study treatment. 
• Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct. 
• Details for completion of each assessment will be included in the Study Manual. 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all eligibility criteria. The investigator will maintain a sc reening log to record details of 
all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable.  
• Procedures conducted as part of the subject’s routine clinical management (eg, blood count)  
and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedure s met the protocol -specified criteria and were performed within the time  
frame defined in the SoA. 
Table 9-1: Volume of Blood to be  Collected from Each Subject 
Type of Sample Volume 
per 
Sample 
(mL) No. of Samples/ 
Subject Total Volume of Blood 
(mL)a 
Part A Part B Part A Part B 
Safety (including screening and 
post treatment assessments)       
- Hematology  4.0 3 4 12.0 16.0 
- Serum chemistry  8.5 3 4 25.5 34.0 
serology ( HIV, HBsAg, 
HCV) 8.5 1 1 8.5 8.5 
serum β-hCG pregnancy test  
(WOCBP only) 4.9 1 2 4.9 9.8 
Pharmacokinetic samples  2.0 8 9 16.0 18.0 
Loss by use of indwelling 
intravenous cannula 1.0 8 9 8.0 9.0 
Total    74.9 95.3 
a Calculated as number of samples multiplied by amount of blood per sample.  
 
Note: An indwelling intravenous cannula may be used for blood sample collection. If a mandarin 
(obturator) is used, blood loss due to discard is not expected. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 41 of 75 
Status: Final v3.0; Date 1 2Dec2019 • If blood samples are collected via an indwelling cannula, an appropriate amount 
(i.e., 1 mL) of fluid slightly greater than the dead space volume of the lock will be removed from the cannula and discarded before each blood sample is taken. After blood sample collection, the cannula will be flushed with saline and charged with a volume equal to the 
dead space volume of the lock. 
• The approximate amount of blood collected from subjects in Part A and Part B will be 75 
mL and 95 mL, respectively. Repeat or unscheduled samples may be taken for safety 
reasons or for tec hnical issues with the samples.  
Daily Procedures  – Part A 
Screening  (Day -30 to Day -15) 
• Sign ICF 
• Record medical and medication history and demographic information (age, sex, race, iris 
color) 
• Review inclusion/exclusion criteria   
• Physical examination  
• Height (cm) and weight  (kg) 
• Vital signs   
• DEQ-5 
• VAS 
• OSDI 
• Clinical laboratory tests (hematology, serum chemistry, urinalysis) 
• Serology (HIV, HBsAg, HCV) 
• Serum pregnancy test for WOCBP; FSH for post-menopausal women 
• Urine drug and alcohol screen s 
• Visual acuity (Snellen)  
• Slit lamp biomicroscopy (w/out mydriatics)  
• MMP-9 (30 minutes before TFBUT and staining tests)  
• TFBUT 
• Corneal fluorescein staining (Baylor)  
• Lissamine green (Baylor + Lid Margin)  
• Aesthesiometer  
• Schirmer I without anesthesia 
• VAS with anesthesia  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 43 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Vital signs   
• VAS 
• PK sampling 
• Slit lamp biomicroscopy (without mydriatics)  
• TFBUT 
• Corneal fluorescein staining (Baylor) 
• Lissamine green (Baylor + Lid Margin)  
• Intraocular Pressure (iCare tonometer)  
• Randomize to study treatment 
Day 1, 0 hour  
• Administer study drug  
Day 1, Po stdose 
• Review AEs and concomitant medications 
• Physical examination at 1 hour 
• Vital signs at 0.5, 1, 2, 4, 8, and 12 hours 
• VAS at 0.5, 1, 2, 4, 8, and 12 hours 
• PK sampling at 0.25, 0.5, 1, 2, 4, 8, and 12 hours 
• Visual acuity at 12 hours 
• Slit lamp biomicrosc opy (without mydriatics) at 1, 2, and 12 hours 
• TFBUT at 2 and 12 hours 
• Corneal fluorescein staining (Baylor) at 2 and 12 hours 
• Schirmer I without anesthesia at 12 hours 
• Intraocular Pressure (iCare tonometer)  at 2 and 12 hours 
• Slit lamp biomicroscopy (w/ my driatics; lens observation) at 12 hours 
• Ophthalmoscopy at 12 hours 
Day 2, 24 hours Postdose 
• Review AEs and concomitant medications 
• Physical Examination   
• Vital signs   
• VAS 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 44 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Clinical laboratory tests (chemistry, hematology, urinalysis)  
• Visual Acuity (Snellen)  
• Slit lamp biomicroscopy (w/out mydriatics)  
• TFBUT 
• Corneal fluorescein staining (Baylor) 
• Schirmer I w/o anesthesia 
• Intraocular Pressure (iCare tonometer)  
• Slit lamp biomicroscopy (w/ mydriatics; lens observation)  
• Ophthalmoscopy 
• Check-out of clinic 
 
Part B 
Screening (Day -30 to Day -15) 
• Sign ICF 
• Record medical and medication history and demographic information 
• Review inclusion/exclusion criteria  
• Physical examination  
• Height (cm) and weight (kg) 
• Vital signs   
• DEQ-5 
• VAS 
• OSDI 
• Clinical laboratory tests (hematology, serum chemistry, urinalysis) 
• Serology (HIV, HBsAg, HCV) 
• Serum pregnancy test for WOCBP; FSH for post-menopausal women 
• Urine drug and alcohol screens  
• Visual acuity (Snellen)  
• Slit lamp biomicroscopy (w/out mydriatics)  
• MMP-9 (30 minutes before TFBUT and staining tests ) 
• TFBUT 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 47 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Ophthalmoscopy at 12 hours 
• Administer study drug at 4, 8, and 12 hours 
Days 2 and 3 
• Review AEs and concomitant medications 
• Physical examination at 0 hour  
• Vital signs at 0, 4, 8, and 12 hours 
• VAS at 0, 4, 8, and 12 hours 
• Visual acuity at 0 hours 
• PK sampling  at predose on Day 2 (ie, Day 1 , 24 hours) 
• Slit lamp biomicroscopy (without mydriatics) at 0 and 12 hours 
• TFBUT at 0 and 12 hours 
• Corneal fluorescein staining (Baylor) at 0 and 12 hours 
• Lissamine green (Baylor + Lid Margin)  at 0 and 12 hours 
• Schirmer I without anesthesia at 0 hours on Day 2 
• Intraocular Pressure (iCare tonometer)  at 0 hour 
• Administer study drug at 0, 4, 8, and 12 hours 
Days 4 through 7 
• Review AEs and concomitant medications 
• Physical examination at 0 hour 
• Vital signs at 0 hour 
• VAS on Day 4 and on Day 7 at 0, 0.5, 1, 2, 4, 8, and 12 hours; VAS on Days 5 and 6 at 0, 
4, 8, and 12 hours 
• PK sampl ing at 0 hour on Day 4  
• Visual acuity at 0 hours 
• Slit lamp biomicroscopy without mydriatics at 0 and 12 hours 
• TFBUT  at 0 and 12 hours 
• Corneal fluorescein staining (Baylor) at 0 and 12 hours 
• Lissamine  green staining (Baylor +Lid Margin) at 0 and 12 hours 
• Administer study drug at 0, 4, 8, and 12 hours 
Day 8, Check Out  
• Review AEs and concomitant medications 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 48 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Physical examination at 0 hour 
• Vital signs at 0 hour 
• VAS  at 0 hour 
• OSDI at 0 hour 
• PK sampl ing at 0 hour 
• Clinical laboratory tests (hematology, serum chemistry, urinalysis ) at 0 hour 
• Visual Acuity (Snellen)  at 0 hour 
• Slit lamp biomicroscopy without mydriatics  at 0 hour 
• TFBUT  at 0 hour 
• Corneal fluorescein staining (Baylor) at 0 hour 
• Lissamine  green staining (Baylor +Lid Margin) at 0 hour 
• Schirmer I  without anesthesia at 0 hour 
• Intraocular pressure  (iCare tonometer)  at 0 hour 
• Slit lamp biomicroscopy w/ mydriatics (lens observation) at 0 hour 
• Ophthalmoscopy at 0 hour 
• Administer study drug at 0 hour 
• Dispense study drug for administration at home 
• Dispense diary  and complete refresher educat ion on completion of diary and self -
administration of study drug 
• Discharge subjects  from clinic  
• Subjects self-administer study drug at 0, 4, 8, and 12 hours each day  
• Subjects record dosing times in diary  
Day 9 through Day 28 
• Subjects self-administer study drug at 0, 4, 8, and 12 hours each day  
• Subjects record dosing times in diary  
Day 15 ±2 and Day 22 ±2  
Subjects come to clinic for the following assessments  (at 0 hour unless otherwise noted): 
• Review AEs and concomitant medications 
• Physical examination  at 0 hour 
• Vital signs  at 0 hour 
• VAS at 0, 4, and 8 hours 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 49 of 75 
Status: Final v3.0; Date 1 2Dec2019 • OSDI at 0 hour 
• Visual acuity at 0 hour 
• Slit lamp biomicroscopy w/out mydriatics  at 0 hour 
• TFBUT at 0 hour 
• Corneal fluorescein staining (Baylor) at 0 hour 
• Lissamine  green staining (B aylor +Lid Margin) at 0 hour 
• Intraocular Pressure (iCare tonometer)  at 0 hour  
• Subjects self -administer study drug at 0, 4, 8, and 12 hours each day  
• Subjects record dosing times in diary  
• Dispense study drug for administration at home 
Day 29 ±2 , EOS 
• Review AEs and concomitant medications 
• DEQ-5 at 0 hour 
• VAS  at 0, 4, and 8 hours 
• OSDI at 0 hour 
• MMP-9 at 0 hour (30 minutes before TFBUT and staining tests ) 
• TFBUT  at 0 hour 
• Corneal fluorescein staining (Baylor) at 0 hour 
• Lissamine  green staining (Baylor +Lid Margin)  at 0 hour  
• Drug administration at 0 hour 
• Clinical laboratory tests (hematology, serum chemistry, urinalysis) at 2 hours  
• Serum pregnancy test for WOCBP only at 2 hours 
• Physical examination, including weight at 4 hours 
• Vital signs  at 4 hours 
• Visual Acuity (Snellen) at 8 hours 
• Slit lamp biomicroscopy without mydriatics at 8 hour  
• Schirmer I  without anesthesia at 8 hours 
• Intraocular pressure  (iCare tonometer)  at 8 hours 
• Slit lamp biomicroscopy w/ mydriatics (lens observation) at 8 hours 
• Ophthalmoscopy at 8 hours 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 50 of 75 
Status: Final v3.0; Date 1 2Dec2019 Day 36 ±2 
• Follow-up telephone call to review AEs and concomitant medications 
 
9.1. Efficacy Assessments  
The following ocular assessments will be done during Part A at the time points listed : 
DEQ-5 Screening, Day -1 
VAS Screening, Day -1, Day 1 (0 (predose), 0.5, 1, 2, 
4, 8, 12, 24 hours) 
OSDI© Screening, Day -1 
MMP-9 (InflammaDry)  Screening, Day -1 
TFBUT Screening, Day 1 ( 0, 2, 12, 24 hours) 
Corneal fluorescein staining (Baylor)  Screening, Day -1, Day 1 (0, 2, 12, 24 hours) 
Lissamine green staining (Baylor +Lid 
Margin [lid wiper epitheliopathy ]) Screening, Day 1 ( 0 hour)  
 
The following ocular assessments will be done during Part B at the time points listed : 
DEQ-5 Screening , Day -1, Day 29  
VAS Screening, Day -1, Day 1 (0, 0.5, 1, 2, 4, 8, 12 hours), Days 2 
and 3 (0, 4, 8, 12 hours) , Days 4 and 7 (0, 0.5, 1, 2, 4, 8, 12 
hours), Days 5 and 6 (0, 4, 8, 12 hours) Day 8 (0 hour), Days 
15, 22 and 29 (0, 4, 8 hours) 
OSDI© Screening , Day -1, Days 8, 15, 22 and 29 at 0 hour 
MMP-9 (InflammaDry)  Screening, Day -1, and 29 (0 hour) 
TFBUT Screening, Day 1 ( 0, 2 and 12 hours),  
Days 2 through 7 (0 and 12 hours) 
Days 8, 15, 22, and 29 (0 hour) 
Corneal fluorescein 
staining (Baylor)  Screening, Day -1, Day 1 (0, 2 and 12 hours),  
Days 2 through 7 (0 and 12 hours) 
Days 8, 15, 22, and 29 (0 hour) 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 51 of 75 
Status: Final v3.0; Date 1 2Dec2019 Lissamine green staining 
(Baylor +Lid Margin  [lid 
wiper epitheliopathy ]) Screening, Day 1  (0 and 12 hours),  
Days 2 through 7 (0 and 12 hours) 
Days 8, 15, 22, and 29 (0 hour) 
Please note: For Part A and  B of this study all OSDI, DEQ-5 and VAS assessments will be 
completed  prior to any laboratory or PK timepoints. TFBUT , Corneal fluorescein staining and 
Lissamine green staining will be scheduled to be completed following any laboratory or PK 
timepoints.  
9.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA. 
9.2.1. Ocular Safety  
The following ocular safety assessments will be conducted during Part A at the time points listed:  
Visual acuity  (Snellen) Screening, Day -1, Day 1 (12 and 24 hours)  
Slit lamp b iomicroscopy  
(w/out mydriatics)  Screening, Day 1 ( 0, 1, 2, 12, 24 hours)  
Aesthesiometer  Screening  
Schirmer I  Screening, Day -1, Day 1 (12 and 24 hours) 
VAS with anesthesia  Screening  
Intraocular pressure 
(iCare tonometer)  Screening, Day 1 ( 0, 2, 12, 24 hours)  
Slit lamp biomicroscopy  
(w/ mydriatics; lens observation) Screening, Day -1, Day 1(12 and 24 hours)  
Ophthalmoscopy  Screening, Day -1, Day 1(12 and 24 hours)  
 
The following ocular safety assessments will be conducted during Part B at the time points listed: 
Visual acuity  (Snellen) Screening, Day -1, Day 1 (12 hours),  
Days 2 through 8, 15, 22, and 29 (0 hour) 
Slit lamp b iomicroscopy  
(w/out mydriatics)  Screening, Day 1 ( 0, 1, 2, 12 hours),  
Days 2 through 7 (0 and 12 hours),  
Days 8, 15, 22, and 29 (0 hour)  
Aesthesiometer  Screening  
Schirmer I  Screening, Day -1, Day 1 (12 hours) ,  
Days 2, 8 and 29 (0 hour) 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 52 of 75 
Status: Final v3.0; Date 1 2Dec2019 VAS with a nesthesia  Screening  
Intraocular pressure  
(iCare tonometer)  Screening, Day 1 (0 and 12 hours),  
Days 2, 3, 8, 15, 22, and 29 (0 hour) 
Slit lamp biomicroscopy  
(w/ mydriatics; lens observation) Screening, Day -1, Day 1 (12 hours),  
Days 8 and 29 (0 hour) 
Ophthalmoscopy  Screening, Day -1, Day 1 (12 hours),  
Days 8 and 29 (0 hour) 
Please note: For Part A and B of this study, a ll ocular safety assessments will be scheduled to be 
performed  following laboratory and  PK time points.  
9.2.2. Physical Examinations 
A complete physical examination will include, at a minimum, assessments of HEENT, the 
Cardiovascular, Respiratory, Gastrointestinal , Dermatologic, and Neurologic systems.  Height and 
weight will also be measured and recorded.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
9.2.3. Vital Signs 
Vital signs will be measured in a semi-supine position after 5 minutes rest and will include oral 
body temperature, systolic and diastolic blood pressure , heart rate,  and respiratory rate. Vital signs 
will be measured before collection of blood samples for laboratory tests or PK. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 53 of 75 
Status: Final v3.0; Date 1 2Dec2019 9.2.4. Clinical Safety Laboratory Assessments 
See Appendix 2 for the list of clinical laboratory tests to be performed and to the  SoA for the 
timing and frequency.  
The investigator must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents. Clinically significant abnormal laboratory findings are 
those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the subject 's condition. 
All laboratory tests with values considered clinically signific antly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer considered clinically significant by the investigator or medical monitor.  
● If such values do not return to normal/baseline within a period of time judged reasonable 
by the investigator, the etiology should be identified and the sponsor notified. 
● All protocol-required laboratory assessments, as defined in Appendix 2
, must be 
conducted in accordance wi th the laboratory manual and the  SoA.  
● If laboratory values from non-protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in subject  management or are considered 
clinically signif icant by the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.  
9.3. Adverse Events  
The definitions of an AE or SAE can be found in Appendix 4 . 
AEs will be recorded from the beginning of the run- in phase. Any medical occurrence before run -
in will be recorded as medical history. AE will be reported by the subject (or, when appropriate, 
by a caregiver, surrogate, or the subject 's legally authorized representative) .  
The investigator and/or designees are responsible for detecting, documenting, and recording  events 
that meet the definition of an AE or SAE and remain responsible for following up  AEs that are 
serious, considered related to the study trea tment or study  procedures , or that caused the subject to 
discontinue the study (see Section 8).  
9.3.1. Time Period and Frequency for Collecting AE and SAE Information  
All SAEs will be collected from the beginning of the run-in phase to the follow-up visit. 
Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the Medical History/Current Medical Conditions section of the case 
report for m (CRF) not the AE section. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours, as indicated in  
Appendix 4 . The investigator will submit any updated SAE data to the sponsor within 24 hours of 
it being available.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 54 of 75 
Status: Final v3.0; Date 1 2Dec2019 Investigators are not obligated to actively seek AE  or SAE in former study subjects. However, if 
the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event to be reasonably related to the study 
treatment or study par ticipation, the investigator must promptly notify the sponsor. 
The method of recording, evaluating , and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 4 . 
9.3.2. Method of Detecting AE s and SAE s 
Care will be taken not to introduce bias when detecting AE s and/or SAEs. Open- ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrences.  
9.3.3. Follow-up of AE s and SAE s 
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAE s, will be followed until resolution, stabiliz ation, the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Section 8.3). Further 
information on follow-up procedures is given in Appendix 4 . 
9.3.4. Regulatory Reporting Requirements for SAE s 
• Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects and the safety of a 
study treatment under clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
sponsor will comply with count ry-specific regulatory requirements relating to safety 
reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent 
Ethics Committee s (IEC), and investigators. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR)  according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary. 
• An investigator who receives an investigator safety report describing a SAE or other 
specific safety information ( eg, summary or listing of SAE s) from the sponsor will review 
and then file it along with the Investigator’s Brochure  and will notify the IRB/IEC, if 
appropriate according to local requirements. 
9.3.5. Pregnancy  
• Details of all pregnancies in female subjects and, if indicated, female partners of male 
subjects will be collected after the start of study treatment and until termination  or 8 weeks 
after birth . 
• If a pregnancy is reported, the investigator should inform the sponsor  within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 5 . 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 56 of 75 
Status: Final v3.0; Date 1 2Dec2019 AUC%extrap percentage of AUC0-∞ that is due to  extrapolation beyond t last 
AUMC 0-last area under the moment curve  from time 0 to time of the last quantifiable 
concentration  
AUMC 0-∞ area under the moment curve from time 0 to infinite time  
MRT0-last mean residence time from time 0 to time of the last quantifiable concentration 
MRT0-∞ mean residence time from time 0 to infinite time  
t1/2 elimination half -life associated with the terminal slope ( λz) of the 
semilogarithmic drug concentration -time curve, calculated as 0.693/ λz 
Vd/F apparent volume of distribution 
CL/F apparent total body clearance  
Rac accumulation ratio s calculated as (Ctrough on day 4) / (C trough on day 2) and (C trough 
on day 8) / (C trough on day 2) (Part B ) 
9.6. Health Economic s 
No Health Economic information will be collected.  
10. Statistical Considerations  
10.1. General Considerations   
The primary statistical analysis of the data will be descriptive in nature. For continuous variables 
this means calculation of the number of observations, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarized by subject counts and related 
percentages. For ordinal -scaled variables, a combination of the above may be employed as 
appropriate: frequency and percentage of observations within a category and means and standard deviations of the scores of the categories. For categorical and ordinal variables, percentages will 
be calculated based on non -missing data.  
10.2. Sample Size Determination   
No formal sample size and/or power calculations were performed for the study, however a sample  
size was chosen based on feasibility to allow total of 92 randomized subjects for Part A (n=32) 
and Part B (n=60). Approximately 32 subjects are expected to complete Part A and 60 subjects are 
expected to complete Part B.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 57 of 75 
Status: Final v3.0; Date 1 2Dec2019 10.3. Populations for Analyses  
For purposes of analysis, the following populations are defined: 
Population Description  
Enrolled  Consist of all enrolled subjects. Subjects who signed the IC F. This 
population will be used in disposition outputs 
Safety set All subjects randomly assigned to study treatment and who take at 
least 1 dose of study treatment. Subjects will be analyzed 
according to the treatment they actually received.  It will be the 
primary population for the safety and tolerability analysis.  
Full analysis s et All subjects randomly assigned to study treatment and who take at 
least 1 dose of study treatment  and have a post -baseline efficacy 
measurement . Subjects will be analyzed according to the treatment 
they actually received.   
Per protocol s et All subjects  who completes the study with at least 75% overall 
dosing compliance and without any other major protocol 
deviations/violations. 
Pharmacokinetic set  All subjects who take at least 1 dose of active drug and have at 
least 1 quantifiable plasma concentration collected postdose 
without important protocol deviations/violations or events thought 
to significantly affect the PK.  
10.4. Statistical Analyses  
All the analysis will be carried out separately for Part A and Part B upon completion of the study 
visit (EOS). Data will be summarized by cohort and across all active dose levels . Complete 
details of the statistical analyses to be performed will be documented in a statistical analysis plan, which will be completed prior to database lock. This document will include more detail of 
analysis populations, summary strategies, and any amendments to the proposed analyses listed here, if necessary. Any changes to the statistical analysis plan will be outlined in the final study 
report.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 58 of 75 
Status: Final v3.0; Date 1 2Dec2019 10.4.1. Efficacy Analyses 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints. All analyses, summaries, and listings will be performed using SAS® software (Version 
9.4 or higher version) 
Endpoint  Statistical Analysis Methods 
Primary Change from baseline (predose on Day 1) in eye dryness  symptom 
(visual analog scale [VAS])  at 4 hours on Day 29  
Change from baseline (predose on Day 1) in corneal fluorescein 
staining (CFS) score at the central zone on Day 29 
Secondary  Changes from baseline in dry eye signs: CFS scores at the central, 
superior, inferior, nasal, temporal and total zones, conjunctival 
lissamine green staining (CLGS) scores at each of 3 nasal and 3 
temporal zone and total zone of bulbar conjunctiva, lid wiper  
epitheliopathy score, and tear film break -up time (TFBUT) at each 
time point tested  
Changes from baseline in dry eye symptoms (VAS [ie, severity of eye dryness, 
discomfort, burning/stinging, sticky feeling, foreign body 
sensation, itching, pain, blurred vision, and sensitivity to light], ocular surface disease index [OSDI
©], Dry eye Questionnaire 5 [DEQ -5] 
scores) at each time point tested  
Biomarker (Matrix Metalloproteinase -9 (MMP-9), InflammaDry®) 
The study eye will be the eye with the greater central zone corneal fluorescein staining  score at 
predose on Day  1. If both eyes meet all of the inclusion and none of the exclusion criteria and the 
central zone corneal fluorescein staining scores are equal, the right eye (OD) will be designated as 
the study eye for the duration of this study.  
The fellow eye (non- study eye) will be treated with the product as per the assigned dosing 
schedule. 
Change in eye assessments will be summarized using descriptive statistics (mean, standard 
deviation, coefficient of variation (%CV), median, minimum, and maximum).  
For this study  co-primary endpoint s will be as follows: the differences between SJP -0132 and 
placebo in changes from baseline  in eye dryness symptom (visual analog scale [VAS])  and change 
from baseline (predose on Day 1) in corneal fluorescein staining (CFS) score at the central zone 
on Day 29.  
Secondary endpoints are changes from baseline in dry eye signs: CFS scores at the superior, 
inferior, nasal, temporal and total zones, conjunctival lissamine green staini ng (CLGS) scores at 
each of 3 nasal and 3 temporal zone and total zone of bulbar conjunctiva, lid wiper epitheliopathy 
score, and tear film break -up time (TFBUT) at each time point tested . Changes from baseline in 
dry eye symptoms (VAS [ie, severity of eye  dryness, discomfort, burning/stinging, sticky feeling, 
foreign body sensation, itching, pain, blurred vision, and sensitivity to light], ocular surface disease 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 59 of 75 
Status: Final v3.0; Date 1 2Dec2019 index [OSDI©], Dry eye Questionnaire 5 [DEQ -5] scores) at each time point tested  and Biomarker 
(Matrix Metalloproteinase -9 (MMP-9), InflammaDry®). 
10.4.2. Safety Analyses 
All safety analyses will be performed on the Safety Population.  
Endpoint  Statistical Analysis Methods 
Primary The number and severity of AEs including abnormal changes from baseline  in 
clinical laboratory results, vital signs, and physical and ophthalmologic 
examinations  
Safety assessments and changes from baseline in vital signs, clinical laboratory results, adverse 
events (AEs), treatment -emergent AEs (TEAEs) , will be summarized using descriptive statistics  
as outlined in the statistical analysis plan including but not limited to  (mean, standard deviation, 
coefficient of variation (%CV), median, minimum, and maximum). Concomitant medications and physical examination findings will be listed.  
10.4.3. Pharmacokinetic  Analyses  
Plasma samples will be analyzed to determine the concentration of SJP -0132. Pharmacokinetic 
variables will be calculated using non- compartmental analysis.  
Individual PK concentrations and PK parameters will be listed. The PK data will be summarized 
descriptively by dose/cohort using appropriate statistics (eg, N, n, arithmetic mean, SD, minimum, median, maximum, geometric mean [PK parameters only, as appropriate], and coefficient of variance [CV%]). Graphical presentati ons will include by -subject and mean concentrations plots 
which will be presented on linear and semi -logarithmic scales. Scatterplots of individual and 
geometric mean exposure parameters [AUC
0-∞, AUC 0-last, and C max] will be presented by dose. 
Additional graphical presentations of PK data may be added at the discretion of the PK scientist  
Part A: Cmax, tmax, tlast, AUC 0-last, AUC 0-∞, AUC %extrap, t1/2, AUMC 0-last, AUMC 0-∞, MRT0-last, MRT0-
∞, Vd/F, CL/F, Cmax,norm, AUC 0-last,norm, AUC 0-∞,norm.  
Part B: Part B: Cmax, tmax, tlast, AUC 0-last, Cmax,norm, and AUC 0-last,norm on Day 1, C trough on Days 2, 4 
and 8, and Rac. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 63 of 75 
Status: Final v3.0; Date 1 2Dec2019 Appendix  2: Clinical Laboratory Tests  
The tests detailed below will be performed by the local laboratory .  
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations. 
Protocol- Required Safety Laboratory Assessments  
Laboratory Assessments Parameters  
Hematology  Platelet Count  RBC Indices : 
MCV 
MCH 
%Reticulocytes  WBC C ount with 
Differential : 
Neutrophils 
Lymphocytes Monocytes 
Eosinophils 
Basophils RBC Count 
Hemoglobin 
Hematocrit  
Clinical Chemistry  BUN 
Potassium 
Creatinine  
Sodium 
Glucose (fasting) 
Calcium  
Total Protein  Aspartate Aminotransferase (AST)/  
Serum Glutamic -Oxaloacetic 
Transaminase (SGOT) 
Alanine Aminotransferase (ALT)/ 
Serum Glutamic -Pyruvic Transaminase 
(SGPT) 
Alkaline phosphatase 
Total and direct bilirubin  
Routine Urinalysis • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, 
nitrite, leukocyte esterase by dipstick 
• Microscopic examination (if blood or protein is abnormal) 
Other Screening Tests  • Follicle-stimulating hormone and estradiol (as needed in 
women of non-childbearing potential only) 
• Urine drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and 
benzodiazepines)] 
• Alcohol urine test  
• Serum human chorionic gonadotropin (hCG) pregnan cy test 
(as needed for women of childbearing potential) at Screening 
and Day 29 (Part B). Urine pregnancy test at Day -1. 
• Serology (HIV antibody, hepatitis B surface antigen 
[HBsAg], and hepatitis C virus antibody)  
Investigators must document their revie w of each laboratory safety report.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 64 of 75 
Status: Final v3.0; Date 1 2Dec2019 Appendix 3: Study Governance Considerations  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following : 
• Consensus ethic al principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure , and other relevant 
documents ( eg, advertisements) must be submitted to an IRB/IEC by the investigator and 
reviewed and approved by the IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/ IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study subjects .  
• The investigator will be  responsible for the following: 
o Providing written  summaries of the status of the study to the IRB/ IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by the IRB/ IEC 
o Notifying the IRB/IEC of SAE s or other significant safety findings as required by 
IRB/IEC procedures 
o Providing oversight of the  conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 
for clinical studies (if applicable), and all other applicable local regulations  
Financial Disclosure  
Investigators and sub-i nvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appro priate regulatory authorities.  Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study. 
Informed Consen t Process  
• The investigator or his/her representative will explain the nature of the study to the subject 
or his/her legally authorized representative and answer all questions regarding the study.  
• Subjects must be informed that their participation is voluntary. Subjects will be required to 
sign a statement of  informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, Health Insurance Portability and Accountability Act ( HIPAA) 
requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the subject  was enrolled in the study and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 65 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Subjects must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the subject or the subject’s legally authorized 
representative.  
Data Protection  
• Subjects will be assigned a unique identifier by the sponsor. Any subject records or datasets 
that are transferred to the sponsor will contain the identifier only; subject names or any 
information which would make the subject  identifiable will not be transferred.  
• The subject  must be informed that his/her personal study-related data will be used by  the 
sponsor in accordance with local data protection law. The level of  disclosure must also be 
explained to the subject .  
• The subject  must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities. 
Publication Policy  
• The results of this study may be published or presented at scientific meetings.  If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before 
submission. This allows the sponsor to protect proprietary information and to provide 
comments.   
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating investigator will be designated by mutual agreement.  
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirem ents. 
Dissemination of Clinical Study Data 
This study and its results will be posted on the US National Institutes of Health’s website 
www.ClinTrials.gov.  
Data Quality Assurance  
• All subject data relating to the study will be reco rded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically ( eg, laboratory data). The investigator 
is responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
• The investigator must maintain accurate documentation (source data) that supports the information entered in  the CRF.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory ag ency inspections and  provide direct access to source data documents.  
• The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 66 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Study monitors will perform ongoing source data verification to conf irm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of subjects are being protected; and that the 
study is being conducted in accordance with the currently  approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.  
• Records and documents, including signed ICF s, pertaining to the conduct of this study must 
be retained by the investigator for 2 years after study comp letion unless local regulations 
or institutional policies require a longer retention period  (ie, at least 2-years after the last 
approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in a n ICH region or at least 2- years have elapsed since 
the formal discontinuation of clinical development of the investigational product ). No 
records may be destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or party without written 
notification to the sponsor.  
Source Documents  
• Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source docu ments are filed at the investigator’s site.  
• Data reported on the CRF  or entered in the eCRF  that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request  previous medical records or transfer 
records, depending on the study. A lso, current medical records must be available.  
 
Study and Site Closure  
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies have 
been collected and a study -site closure visit has been performed . 
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the sponsor or investigator may include but are  not 
limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of subjects by the investigator 
• Discontinuation of further study treatment development  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 67 of 75 
Status: Final v3.0; Date 1 2Dec2019 Appendix 4: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow- up, and Reporting  
Definition of AE 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study subject, temporally 
associated with the use of study treatment , whether or not considered related to the study 
treatment . 
• A treatment -emergent adverse event (TEAE) is any AE that occurs or worsens in either 
intensity or frequency after exposure to study drug in the treatment phase. 
• NOTE: An AE can therefore be any  unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study treatment. 
 
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology , clinical chemistry, or urinalysis) or other 
safety assessments ( eg, electrocardiogram , radiological scans, vital signs measurements), 
including those that worsen from baseline, considered  clinically significant in the medical 
and scientific judgment of the investigator ( ie, not related to progression of underlying 
disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after study treatment administration even though it 
may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment 
or a concomitant medication. O verdose per se will not be reported as an AE/SAE unless it 
is an intentional overdose taken with possible suicidal/self- harming intent.  Such overdoses 
should be report ed regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments.  
However, the signs, symptoms, and/or clinical sequelae r esulting from lack of efficacy  will 
be reported as AE or SAE  if they fulfil the definition of an AE or SAE.  
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 68 of 75 
Status: Final v3.0; Date 1 2Dec2019 Events NOT Meeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the subject ’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the subject’s condition.  
• Medical or surgical procedure ( eg, endoscopy, appendectomy): the condition t hat leads to 
the procedure is the AE. 
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
Definition of SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met ( eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death 
b. Is life-threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject 
was at risk of death at the time of the event.  It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires  inpatient  hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the subject has been detained (usually involving at least 
an overnight stay) at the hospital or emergency ward for observation and/or treatment that would 
not have been appropriate in the physician’s office or out patient setting.  Complications that 
occur during hospitalization are AE s. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious.  When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE. 
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 69 of 75 
Status: Final v3.0; Date 1 2Dec2019 • This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma ( eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect 
f. Other situations: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospitalization but may jeopardize the 
subject or may require medical or surgical intervention to prevent one of the other outcomes 
listed in the above definition. These events should usually be considered serious. 
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.
 
Recording and AE and/or SAE 
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all  
documentation ( eg, hospital progress notes, laboratory  reports, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF  (eg, event 
term, date and time of onset, date and time of resolution, anatomical site or system) . If the 
AE/SAE is to an eye, the study eye or fellow eye must be identified.  
• It is not acceptable for the investigator to send photocopies of the subject’s medical records 
to Senju in lieu of completion of the AE/SAE CRF page. 
• There may be instances when copies of medical records for certain cases are requested by Senju. In this case, all subject identifiers, with the exception of the subject  number, will be 
redacted on the copies of the medical records before  submission to Senju . 
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual 
signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories:  
• Grade 1 ( Mild): asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 70 of 75 
Status: Final v3.0; Date 1 2Dec2019 • Grade 2 ( Moderate ): minimal, local or non-invasive intervention indicated; limiting age  
appropriate instrumental ADL* . 
• Grade 3 ( Severe): medically s ignificant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self -care 
ADL. 
• Grade 4 (Life threatening): urgent intervention indicated 
• Grade 5 (Death) : death related to AE  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
* Activities of daily living  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each 
occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts , evidence, and/ or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s) , concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study treatment administration 
will be considered and investigated. 
• The investigator will also consult the Investigator ’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment. 
• For each AE/SAE , the investigator  must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to Senju. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to Senju. 
• The investigator may change his/her opinion of causality in light of follow -up information 
and send a SAE follow- up report with the updated causality assessment . 
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 71 of 75 
Status: Final v3.0; Date 1 2Dec2019 Follow-up of AE s and SAE s 
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Senju to 
elucidate the nature and/or causality of the AE or SAE  as fully as possible . This may inc lude 
additional laboratory tests or investigations, histopathological examinations , or consultation 
with other health care professionals. 
• Drug related AEs or SAEs will be followed up until resolution, stabilization, or the event is 
otherwise explained, or the subject is lost to follow -up. 
• Non-drug-related AEs  or SAEs will not be followed after the telephone follow -up call is 
complete. Any non-drug-related AEs or SAEs , that have not been resolved, stabiliz ed, or 
otherwise explained  by the follow -up telephone visit will be referred to the subjects  Primary 
Care Physician for ongoing care.  
• If a subject dies during participation in the study or during a recognized follow -up period, 
the investigator will provide Senju with a copy of any p ost-mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed CRF. 
• The investigator will submit any updated SAE data to Senju within 24 hours of receipt of  
the information . 
 
Reporting of SAEs  
SAE Reporting to Senju via an E lectronic Data Collection Tool 
• The primary mechanism for reporting an SAE to Senju will be the electronic data collection 
tool. 
• If the electronic system is unavailable for more than 24 hours, then the  site will use the 
paper SAE data collection tool (see next section) . 
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be tak en 
off-line to prevent the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE from a study subject or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off -line, 
then the site can report this information on a paper SAE form  (see next section) or to the 
Senju by telephone.  
• Contacts for SAE report ing can be found in the Study Reference Manual . 
 
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 72 of 75 
Status: Final v3.0; Date 1 2Dec2019 SAE Reporting  to Senju via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to Senju . 
• In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pag es within the designated reporting time frames. 
• Contacts for SAE reporting can be found in the Study Reference manual  
  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 73 of 75 
Status: Final v3.0; Date 1 2Dec2019 Appendix  5: Contraceptive Guidance and Collection of Pregnancy Information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below) . 
 
Women in the following cate gories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following: 
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy 
Note:  Documentation can come from the site personnel’s: review of the subject ’s medical 
records, medical examination, or medical history interview. 
 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be us ed to confirm a postmenopausal state in women not using hormonal 
contracep tion or hormonal replacement therapy (HRT). However , in the absence of 12 
months of amenorrhea, a single FSH measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-hormonal highly effecti ve contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
 
Contraception Guidance  
Male subjects  
• Male subjects  with female partners of childbearing potential are eligible to participate if 
they agree to ONE of the following [during the protocol -defined time frame in Section 
6.1]:  
Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle (abstinent on a 
long term and persistent basis ) and agree to remain abstinent  
• Agree to use a male condom plus partner use of a contraceptive method with a failure rate 
of <1% per year as described below when having penile -vaginal intercourse with a woman 
of childbearing potential who is not currently pregnant  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 74 of 75 
Status: Final v3.0; Date 1 2Dec2019 Men with a pregnant or breast feeding partner must agree to remain abstinent from penile -vaginal 
intercourse or use a male condom during each episode of penile penetration [during the protocol -
defined time frame]   
Female subjects 
Female subjects  of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described below. 
Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently and correctly.  
 Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation 
• Oral  
• Intravaginal  
• Transdermal  
 Progestogen only hormonal contraception associated with inhibition of  ovulation  
• Oral  
• Injectable  
Highly Effective Methods That Are User Independent  
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulationIntrauterine device (IUD)  
• Intrauterine hormone- releasing system (IUS)  
Bilateral tubal occlusion  
 Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.   
 Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the 
study and the preferred and usual lifestyle of the subject.  
NOTES:  
a) Typical use failure rates may differ from those when used consistently and correctly. Use 
should be consistent with local regulations regarding the use of contraceptive methods for 
subjects participating in clinical studies.  
b) Hormonal contraception may be susceptible to interaction with the study treatment, which 
may reduce the efficacy of the contraceptive method. In this case, two highly effective methods 
of contraception should be utilized during the treatment period and for at least 30 days after 
the last dose of study treatment  
CONFIDENTIAL   Senju Pharmaceutical Co., Ltd.  
Protocol SJP-0132/1-01 
Page 75 of 75 
Status: Final v3.0; Date 1 2Dec2019 Pregnancy Testing  
WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive pregnancy test. 
Pregnancy testing will be performed whenever a menstrual cycle is missed or when pregnancy is 
otherwise suspected  
 Collection of Pregnancy Information  
Male subjects  with partners who become pregnant  
• The investigator will attempt to collect pregnancy information on any male subject’s female 
partner who becomes pregnant while the male subject is in this study. This applies only to 
male subjects  who receive SJP-0132. 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner’s pregnancy. The female 
partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the sponsor. Generally, the follow- up will 
be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the 
pregnancy will be reported regardless of fetal status (presence or absence of anoma lies) or 
indication for the procedure.  
Female Subjects who become pregnant  
• The investigator will collect pregnancy information on any female subject who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the sponsor within 24 hours of learning of a subject's pregnancy. The 
subject will be followed to determine the outcome of the pr egnancy. The investigator will 
collect follow -up information on the subject and the neonate and the information will be 
forwarded to the sponsor. Generally, follow -up will not be required for longer than 6 to 8 
weeks beyond the estimated delivery date. Any  termination of pregnancy will be reported, 
regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion 
is always considered to be an SAE and will be reported as such. Any post -study pregnancy -
related SAE considered reasonably related to the study treatment by the investigator will be reported to the sponsor as described in Section 9.3. While the investigator is not obligated to 
actively seek this information in former study subjects, he or she may learn of an SAE through 
spontaneous reporting.  
• Any female subject who becomes pregnant while participating in the study will be withdrawn 
from the study.  